Laboratorios Almirall can help patients with a lot of ailments. The pharmaceutical company develops, manufactures, and markets drugs for a wide range of conditions affecting the digestive, central nervous, respiratory, and cardiovascular systems. Products include ebastine (antihistamine), aceclofenac (anti-inflammatory), and almotriptan (anti-migraine drug). The company, which is the leading drugmaker in Spain, operates from offices in Europe and Mexico and markets its drugs in more than 70 countries. Laboratorios Almirall is currently focusing its research efforts on treating asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, and dermatological problems, among others.

Amgen Inc. company was founded in 1980 and is based in Thousand Oaks, California. Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada.

Immucor, Inc. company was founded in 1982 and is based in Norcross, Georgia. Immucor, Inc., an in vitro diagnostics company, engages in the development, manufacture, and sale of reagents and automated systems. Its products are used by hospitals, reference laboratories, and donor centers to detect and identify certain properties of the cell and serum components of human blood for the purpose of blood transfusion. The company's reagent products are used in tests to identify blood group and type; to detect and identify red cell antibodies or red cell antigens; to detect and identify platelet antibodies; and to determine blood compatibility. It offers various test systems, including Capture-P, a platelet antibody detection system; Capture-R, a red cell antibody detection system; Capture-R Select, which is used for antibody screening, identification, phenotyping, cross matching, and in the weak D test; and Capture-CMV and Capture-S, which are tests for infectious diseases. Immucor, Inc. also offers automated analyzers comprising Galileo, which provides an automated solution to perform various routine blood bank tests, such as blood grouping, antibody screening, crossmatch, direct antiglobulin test, antibody identification, and cytomegalovirus and syphilis screening; Galileo Echo, a compact bench top automated instrument for the small to medium-sized hospitals, and blood banks; and Capture Workstation, a semi-automated processor, which has semi-automated components for performing capture assays manually. The company offers its medical instruments on rent. It sells its products directly in the United States, Canada, western Europe, and Japan; and through distributors internationally.

Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company's commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The company's products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and Ereska™ (intranasal ketamine).

Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

MDRNA, Inc. company was founded in 1983 and is headquartered in Bothell, Washington. MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.